C. McClure , M. Bollen , L. Buttolph , E. Stack , B.O. Langley , D. Hanes , K.M. Wright , D. Tibbitts , R. Bradley
{"title":"Pau d ' Arco (Tabebuia avellanedae)治疗原发性痛经的安全性和耐受性:一项针对18-45岁成年人的单臂、开放标签试验","authors":"C. McClure , M. Bollen , L. Buttolph , E. Stack , B.O. Langley , D. Hanes , K.M. Wright , D. Tibbitts , R. Bradley","doi":"10.1016/j.aimed.2022.04.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p><span>To evaluate the safety and tolerability of encapsulated </span><span><em>Tabebuia</em><em> avellanedae</em></span><span> in generally healthy women aged 18–45 with primary dysmenorrhea.</span></p></div><div><h3>Methods</h3><p>A single arm, open-label trial was conducted in which 1050 mg/day of encapsulated <em>Tabebuia avellanedae</em><span><span> (Pau d′Arco) was administered to twelve healthy women aged 18–45 for eight weeks. The primary outcome was safety and tolerability as measured by standardized adverse events scales and serial collection of laboratory markers to assess general health, prothrombin times, and the presence or absence of anemia. Secondary outcomes included pain intensity, </span>quality of life<span>, and pain interference measured by the Visual Analog Scale (VAS), the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 survey, and the PROMIS Visual </span></span><em>Sexual Function and Satisfaction: Interfering Factors</em> survey, respectively. Exploratory outcomes included serum concentration of high-sensitivity C-reactive protein as a marker of systemic inflammation.</p></div><div><h3>Results</h3><p>Seventy-five percent of participants (n = 9/12) completed the study. Seventy-five percent of study participants (n = 9/12) reported an adverse event, most of which were characterized as mild, and none were determined to be a Food and Drug Administration (FDA) serious adverse event. Most laboratory markers stayed within normal limits throughout the study period with a few clinically mild abnormalities. There was a significant decrease in pain intensity compared to baseline after the first dose (p < .01), after 4 weeks of treatment (p < .01), and after 8 weeks of treatment (p < .01). Over the 8-week intervention period, pain interference, quality of life, and sexual function and satisfaction scores improved nonsignificantly and hs-CRP decreased nonsignificantly.</p></div><div><h3>Conclusions</h3><p><em>Tabebuia avellanedae</em> supplementation of 1050 mg/day dose for eight weeks in generally healthy women aged 18–45 with primary dysmenorrhea was generally safe, associated with moderate tolerability, and associated with significant improvements in pain intensity scores. Future studies examining the safety and efficacy of <em>Tabebuia avellanedae</em> on primary dysmenorrhea are warranted.</p></div>","PeriodicalId":7343,"journal":{"name":"Advances in integrative medicine","volume":"9 3","pages":"Pages 159-166"},"PeriodicalIF":1.7000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and tolerability of Pau d′ Arco (Tabebuia avellanedae) for primary dysmenorrhea: A single-arm, open-label trial on adults ages 18–45\",\"authors\":\"C. McClure , M. Bollen , L. Buttolph , E. Stack , B.O. Langley , D. Hanes , K.M. Wright , D. Tibbitts , R. Bradley\",\"doi\":\"10.1016/j.aimed.2022.04.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p><span>To evaluate the safety and tolerability of encapsulated </span><span><em>Tabebuia</em><em> avellanedae</em></span><span> in generally healthy women aged 18–45 with primary dysmenorrhea.</span></p></div><div><h3>Methods</h3><p>A single arm, open-label trial was conducted in which 1050 mg/day of encapsulated <em>Tabebuia avellanedae</em><span><span> (Pau d′Arco) was administered to twelve healthy women aged 18–45 for eight weeks. The primary outcome was safety and tolerability as measured by standardized adverse events scales and serial collection of laboratory markers to assess general health, prothrombin times, and the presence or absence of anemia. Secondary outcomes included pain intensity, </span>quality of life<span>, and pain interference measured by the Visual Analog Scale (VAS), the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 survey, and the PROMIS Visual </span></span><em>Sexual Function and Satisfaction: Interfering Factors</em> survey, respectively. Exploratory outcomes included serum concentration of high-sensitivity C-reactive protein as a marker of systemic inflammation.</p></div><div><h3>Results</h3><p>Seventy-five percent of participants (n = 9/12) completed the study. Seventy-five percent of study participants (n = 9/12) reported an adverse event, most of which were characterized as mild, and none were determined to be a Food and Drug Administration (FDA) serious adverse event. Most laboratory markers stayed within normal limits throughout the study period with a few clinically mild abnormalities. There was a significant decrease in pain intensity compared to baseline after the first dose (p < .01), after 4 weeks of treatment (p < .01), and after 8 weeks of treatment (p < .01). Over the 8-week intervention period, pain interference, quality of life, and sexual function and satisfaction scores improved nonsignificantly and hs-CRP decreased nonsignificantly.</p></div><div><h3>Conclusions</h3><p><em>Tabebuia avellanedae</em> supplementation of 1050 mg/day dose for eight weeks in generally healthy women aged 18–45 with primary dysmenorrhea was generally safe, associated with moderate tolerability, and associated with significant improvements in pain intensity scores. Future studies examining the safety and efficacy of <em>Tabebuia avellanedae</em> on primary dysmenorrhea are warranted.</p></div>\",\"PeriodicalId\":7343,\"journal\":{\"name\":\"Advances in integrative medicine\",\"volume\":\"9 3\",\"pages\":\"Pages 159-166\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in integrative medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212958822000374\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in integrative medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212958822000374","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Safety and tolerability of Pau d′ Arco (Tabebuia avellanedae) for primary dysmenorrhea: A single-arm, open-label trial on adults ages 18–45
Objectives
To evaluate the safety and tolerability of encapsulated Tabebuia avellanedae in generally healthy women aged 18–45 with primary dysmenorrhea.
Methods
A single arm, open-label trial was conducted in which 1050 mg/day of encapsulated Tabebuia avellanedae (Pau d′Arco) was administered to twelve healthy women aged 18–45 for eight weeks. The primary outcome was safety and tolerability as measured by standardized adverse events scales and serial collection of laboratory markers to assess general health, prothrombin times, and the presence or absence of anemia. Secondary outcomes included pain intensity, quality of life, and pain interference measured by the Visual Analog Scale (VAS), the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 survey, and the PROMIS Visual Sexual Function and Satisfaction: Interfering Factors survey, respectively. Exploratory outcomes included serum concentration of high-sensitivity C-reactive protein as a marker of systemic inflammation.
Results
Seventy-five percent of participants (n = 9/12) completed the study. Seventy-five percent of study participants (n = 9/12) reported an adverse event, most of which were characterized as mild, and none were determined to be a Food and Drug Administration (FDA) serious adverse event. Most laboratory markers stayed within normal limits throughout the study period with a few clinically mild abnormalities. There was a significant decrease in pain intensity compared to baseline after the first dose (p < .01), after 4 weeks of treatment (p < .01), and after 8 weeks of treatment (p < .01). Over the 8-week intervention period, pain interference, quality of life, and sexual function and satisfaction scores improved nonsignificantly and hs-CRP decreased nonsignificantly.
Conclusions
Tabebuia avellanedae supplementation of 1050 mg/day dose for eight weeks in generally healthy women aged 18–45 with primary dysmenorrhea was generally safe, associated with moderate tolerability, and associated with significant improvements in pain intensity scores. Future studies examining the safety and efficacy of Tabebuia avellanedae on primary dysmenorrhea are warranted.
期刊介绍:
Advances in Integrative Medicine (AIMED) is an international peer-reviewed, evidence-based research and review journal that is multi-disciplinary within the fields of Integrative and Complementary Medicine. The journal focuses on rigorous quantitative and qualitative research including systematic reviews, clinical trials and surveys, whilst also welcoming medical hypotheses and clinically-relevant articles and case studies disclosing practical learning tools for the consulting practitioner. By promoting research and practice excellence in the field, and cross collaboration between relevant practitioner groups and associations, the journal aims to advance the practice of IM, identify areas for future research, and improve patient health outcomes. International networking is encouraged through clinical innovation, the establishment of best practice and by providing opportunities for cooperation between organisations and communities.